Carcinome rénal métastatique, retour vers le futur.. [Metastatic renal cell carcinoma, back to the future]

Details

Ressource 1Download: RMS_519_994.pdf (4549.17 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_51ABC794800F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Carcinome rénal métastatique, retour vers le futur.. [Metastatic renal cell carcinoma, back to the future]
Journal
Revue medicale suisse
Author(s)
Martins F., Berthold D.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
18/05/2016
Peer-reviewed
Oui
Volume
12
Number
519
Pages
994-998
Language
french
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Renal cell carcinoma (RCC) is composed of several histopathological entities. There are more than 1,000 new cases in Switzerland every year, one third of which are diagnosed at an advanced stage. The development of chemotherapy had no impact on its overall prognosis. Since the mid-2000s, treatment of metastatic RCC was transformed by the arrival of targeted therapies. In the early 90s, high dose interleukine-2 (IL-2) allowed first cases of complete response, demonstrating the immunogenicity of RCC. More than twenty years after its first steps, immunotherapy progressed due to the recently approved nivolumab (an anti-PD1 monoclonal antibody) in second line of treatment. This review outlines the progress that has been made in the understanding and treatment of this pathology.
Keywords
Antibodies, Monoclonal/therapeutic use, Antineoplastic Agents/therapeutic use, Carcinoma, Renal Cell/diagnosis, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/pathology, Humans, Immunotherapy/methods, Kidney Neoplasms/diagnosis, Kidney Neoplasms/drug therapy, Kidney Neoplasms/pathology, Neoplasm Metastasis, Neoplasm Staging, Nivolumab, Prognosis, Switzerland
Pubmed
Create date
30/11/2016 21:11
Last modification date
12/12/2024 15:02
Usage data